SCHEMBL1043772

SCHEMBL1043772

Cc1noc(C)c1S(=O)(=O)NC1CCCC(Nc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 0.61
GSK3B P49841 12/20 0.61
PRKACA P17612 13/20 0.54
HIPK2 Q9H2X6 13/20 0.54
DAPK3 O43293 12/20 0.54
PRKX P51817 12/20 0.54
DYRK1A Q13627 12/20 0.54
PKN2 Q16513 12/20 0.54
MINK1 Q8N4C8 12/20 0.54
MAP4K5 Q9Y4K4 12/20 0.54
CDK2 P24941 12/20 0.54
CDK9 P50750 12/20 0.54
PAK4 O96013 11/20 0.54
MAP4K2 Q12851 11/20 0.54
STK3 Q13188 11/20 0.54
MAP4K4 O95819 11/20 0.54
CLK2 P49760 11/20 0.54
CDK5 Q00535 11/20 0.54
STK17A Q9UEE5 11/20 0.54
CLK4 Q9HAZ1 10/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045773 0.93 CDC7 (0.62) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1044456 0.86 CDC7 (0.65) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1044546 0.85 CDC7 (0.73) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1051746 0.83 CDC7 (0.64) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1045517 0.83 CDC7 (0.66) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1042995 0.83 CDC7 (0.70) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1045137 0.82 CDC7 (0.65) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1044014 0.82 CDC7 (0.66) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1042719 0.80 CDC7 (0.66) CDC7GSK3BPRKACAHIPK2DAPK3
SCHEMBL1043895 0.80 CDC7 (0.80) CDC7GSK3BPRKACAHIPK2DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP claimed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885GSK3B 442/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.